Scientists Discover a New Gut Disease, Bacterial Constipation – Here’s What It Is
Researchers at Nagoya University in Japan identified two common gut bacteria that play a central role in bacterial constipation: Bacteroides thetaiotaomicron and Akkermansia muciniphila. According to their findings, these bacteria work together to break down the protective mucus layer in the colon, reducing lubrication and drying out stool – ultimately leading to hard, difficult-to-pass feces.
This discovery introduces what scientists are now describing as a new gut disease, shifting the way chronic constipation may be understood in certain patients.
What Is Bacterial Constipation?
Bacterial constipation is a newly identified gut condition caused by excessive degradation of mucin – the gel-like mucus that lines and protects the colon. Under normal circumstances, this mucus layer keeps the colon lubricated and ensures that stool remains adequately hydrated for smooth passage.
However, the Nagoya University research demonstrated that specific bacterial interactions can strip sulfate groups from mucin and then consume it, weakening the protective barrier. Without sufficient mucus, stool becomes dry and hardened, making bowel movements painful and difficult.
This mechanism differs from traditional constipation, which is often attributed to slow bowel motility, low fiber intake, dehydration, or hormonal imbalance.
The Role of the Two Key Bacteria
1. Bacteroides thetaiotaomicron
This bacterium produces enzymes called sulfatases that remove sulfate groups from mucin. Sulfation normally protects mucin from degradation. Once these sulfate groups are removed,
2. Akkermansia muciniphila
After desulfation occurs, this bacterium consumes the exposed mucin as a nutrient source. While Akkermansia muciniphila is often considered beneficial in metabolic health research, its overactivity in this specific context may contribute to pathological mucus loss.
Together, these microbes create a “gut-drying” effect – the defining feature of bacterial constipation.
Why This Discovery Matters
1. A New Mechanism for Chronic Constipation
This New Gut Disease suggests that constipation is not always a motility disorder. In some individuals, the problem may lie in mucus depletion rather than slowed transit time.
2. Explains Treatment Resistance
Patients who do not respond to laxatives or prokinetic drugs may have underlying mucosal barrier damage instead of purely functional constipation.
3. Potential Link to Neurological Disorders
The researchers observed that this mechanism may also help explain constipation frequently seen in conditions such as Parkinson’s disease, where gut symptoms often precede neurological manifestations.
How Is It Different From Regular Constipation?
Traditional constipation may be associated with:
- Low dietary fiber
- Inadequate hydration
- Sedentary lifestyle
- Pelvic floor dysfunction
- Slow colonic transit
In contrast, bacterial constipation involves:
- Microbial enzyme activity
- Loss of mucosal lubrication
- Excessive mucin degradation
- Stool dehydration despite normal transit
This distinction is clinically important because management strategies may differ.
Future Implications for Treatment
The Nagoya University team also found that blocking the bacterial sulfatase enzyme could prevent mucus degradation in experimental models. This opens the possibility of:
- Enzyme inhibitors targeting sulfatase activity
- Microbiome-modulating therapies
- Precision probiotics
- Personalized gut microbiome testing
As research evolves, gastroenterologists may begin to evaluate chronic constipation cases through a microbial lens rather than relying solely on transit studies.
Clinical Perspective
As a gastroenterologist, it is important to recognize that bacterial constipation does not replace traditional constipation diagnoses but may represent a distinct subgroup of patients with microbiome-driven pathology.
Further human studies are needed to establish diagnostic criteria, prevalence rates, and standardized treatment protocols. However, this discovery reinforces the growing importance of the gut microbiome in digestive health.
Conclusion
The identification of bacterial constipation marks a significant advancement in gastroenterology. This newly described New Gut Disease highlights how specific bacterial interactions can disrupt the colon’s protective mucus barrier, leading to hardened stools and chronic symptoms.
While more research is needed, this breakthrough could pave the way for targeted microbiome-based therapies and a more personalized approach to managing constipation.
Source:
